Alphatec Holdings, Inc. · NASDAQ:ATEC
Alphatec — Q2 2026 Earnings Presentation
24 slides from Alphatec's earnings presentation, Aug 4, 2026
Slide 1: Q2 2026 Financial Results
Ontec INFORMED BY €ON Q2 2026 FINANCIAL RESULTS PAT MILES, CHAIRMAN & CEO | TODD KONING, EVP & CFO | AUGUST 4,-2026
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such statements are based on management's current expectations and are subject to a number of risks and
Slide 3: Industry-Leading Profitable Growth: Q2'2026 Highlights
INDUSTRY- LEADING PROFITABLE GROWTH Q2'2026 HIGHLIGHTS 3 | Reference non-GAAP reconciliation in appendix $214M Total Revenue 20% Case Volume Growth 17% Surgical Revenue Growth $17M = $36M EOS Revenue Adjusted EBITDA 24 uy Net New Surgeo: Growth $1 Free Cash Generat ed odec neo er COS
Slide 4: Q2 Revenue Performance
4 Q2 REVENUE PERFORMANCE STRONG REVENUE GROWTH DRIVEN BY SURGICAL VOLUME Q2 2026 yoy$ Surgical Revenue $196M $28M EOS Revenue $17M - TOTAL REVENUE $214M $28M | May not foot due to rounding | Reference non-GAAP reconciliation in appendix YOY% 17% 0% 15% $28M Surgical Revenue YoY $ Growth 20% surgical
Slide 5: Q2 2026 Non-GAAP P&L Highlights
5 Q2 2026 NON-GAAP P&L HIGHLIGHTS DISCIPLINED EXECUTION DRIVING PROFITABILITY—EBITDA GROWTH OUTPACING REVENUE GROWTH Q2 2026 yoy TOTAL REVENUE $214M 15% Gross Margin % 72.5% 260 bps R&D % 6.8% (80 bps) SG&A % 56.2% (180 bps) Total Operating Expense % 63.0% (260 bps) OP PROFIT MARGIN % 9.4% 510 bps A
Slide 6: Q2 Balance Sheet
Q2 BALANCE SHEET GENERATING CASH FLOW WITH AN IMPROVED CAPITAL STRUCTURE BALANCE SHEET Q2 2026 CASH FLOW Q2 2026 Cash $119M Operating Cash Flow? $34M Available Borrowing* $85M Inventory and PP&E ($33M) CASH + AVAILABLE CASH $204M FREE CASH FLOW? $1M v Generated positive free cash flow TERM LOAN & RE
Slide 7: 2026 Revenue Outlook
2026 REVENUE OUTLOOK CONFIDENCE IN THE FULL YEAR WITH GROWTH DRIVEN BY STRONG SURGICAL DEMAND $882M ——— Total Revenue Surgical Revenue $805M 17% YoY Topline Growth EOS Revenue $77M 0% TOTALREVENUE $882M 15% odec wonnas EOS
Slide 8: 2026 Financial Outlook
2026 FINANCIAL OUTLOOK AFFIRMING.REVENUE & RAISING PROEITABILITY GROWTH LEADERSHIP POWERFUL LEVERAGE FREE CASH FLOW Total revenue; Adjusted EBITDA; Investing in growth and 15% growth 16% margin generating cash INDUSTRY-LEADINGPROFITABLE- GROWTH & INNOVATION odec
Slide 9: Our Strategy Remains Steadfast
OUR STRATEGY REMAINS STEADFAST DELIVERING ON THE FUNDAMENTALS OF OUR LONG-TERM GROWTH ALGORITHM CREATE CLINICAL DISTINCTION COMPEL SURGEON ADOPTION EXPAND, ELEVATE & ENABLE SALES FORCE Architect unparalleled procedural solutions that improve patient outcomes Earn loyalty through differentiated train
Slide 10: Procedural Clinical Distinction
10 PROCEDURAL CLINICAL DISTINCTION COMPELLING SURGEON ADOPTION — 20% CASE VOLUME & 24% NET NEW SURGEON GROWTH YOY ACCESS & POSITIONING SAFEOP® tare: Is f VALENCE® ~~? INTRAOPERATIVE TECHNOLOGIES inrersony ye ( Tid IMPLANTS EOS INSIGHT® PATIENT-SPECIFIC IMPLANTS % ORGANIC INNOVATION MACHINE™ CERVICAL
Slide 11: Surgeon Users
SURGEON USERS 2018 «492019 2020 .2021. 2022 2023 2024 2025 DISTINCTION SURGEON UTILIZATION EARNS TRUST. TRUST EXPANDS gE U | i LI ZA T 10 N @ 2018 2019 2020 2021 2022 2023 2024 # 2025 AVG CASES/ SURGEON
Slide 12: EOS Imaging Is the Entry Point
EOS IMAGING IS THE ENTRY POINT ADVANCING FROM AN IMAGING PLATFORM 10 AN INFORMATICS MOAT AT LEADING INSTITUTIONS ACCESS Entryway into leading, most prestigious institutions and KOL surgeons. Establishes ATEC rep presence in high- value strategic accounts
Slide 13: EOS Data Advantage Is Undeniable
EOS DATA ADVANTAGE IS UNDENIABLE CONVERTING ACCESS INTO HARDWARE PULL-THROUGH AND STRUCTURED LONGITUDINAL DATA CLINIC INTEGRATION Embedded beyond the 0.R. into Li pre-and post-op clinical 9 0 AVERAGE REVENUE GROWTH workflow, becoming standard | ACROSS ESTABLISHED ATEC USERS practice for entire care
Slide 14: Indispensable in the O.R.
INDISPENSABLE IN THE O.R. = Ze see i / \ " a a % ‘> } , ‘ne /ALENCE ee GAFEOP
Slide 15: Solutions for Complex Deformity
SOLUTIONS FOR COMPLEX DEFORMITY PROCEDURALIZED HARDWARE & INFORMATICS PURPOSE-BUILT FOR THE MOST COMPLEX OF CASES MOST-COVETED IMAGING AUTOMATED ALIGNMENT 3D SURGICAL PLANNING WITH AXIAL ROTATION ; { ane TEE = &i~ DIAGNOSIS & PLANNING 4 Insight PEDIATRIC POSITIONING INTRAOP RECONCILIATION OF CORRECT
Slide 16: Focal Replication of Clinical Model
FOCAL REPLICATION OF CLINICAL MODEL EXPORTING & SCALING CLINICAL DISTINCTION TO UNLOCK GROWTH IN MOST ATTRACTIVE >» VALIDATIO = CLINICAL TH STRONG OUS SURGICAL GR La
Slide 17: Growth Catalysts
GROWTH CATALYSTS PROCEDURAL INNOVATION DRIVE CONVOYED SALES THROUGH NEW PRODUCTS LATERAL DISTINCTION EXPAND NEW SURGEON FUNNEL AND UTILIZATION OF OUR ENTIRE PORTFOLIO EOS & EOS INSIGHT” SECURE NEW ACCESS, SCALE MATURE ACCOUNTS, EXPAND UTILIZATION DEFORMITY & PEDIATRICS GROW INFLUENCE AND LEADERSHIP
Slide 18: The Preferred Destination in Spine
OAeC INFORMED BY €OS F THE PREFERRED DESTINATION IN SPINE.
Slide 19: Appendix
APPENDIX
Slide 20: Supplemental Financial Information: Historical GAAP P&L Trend
SUPPLEMENTAL FINANCIAL INFORMATION eC HISTORICAL GAAP P&L TREND - CONSOLIDATED ($000's) Q124 Q224 9324 424 2024 2025 Q126 Revenue from products and services $ 136477 $ 145,573 $ 150719 $ 176,793 $ 611562 $ 169,180 $ 185,544 $ 196,503 $ 212,928 $ 764,155 $ 192,108 $ 213,513 Cost of sales 41,126 42379
Slide 21: Supplemental Financial Information: Non-GAAP Reconciliation
SUPPLEMENTAL FINANCIAL INFORMATION [@C NON-GAAP RECONCILIATION - CONSOLIDATED ($000's) NON-GAAP GROSS PROFIT & GROSS MARGIN Q124 Q224 Gross Profit, GAAP S 97,351 $ 102594 $ 102.729 $ 121588 $ 424,262 $ 115,996 $ 129,101 $ 137,300 $ 149.491 $ 531,888 $ 136476 $ 154,098 + Amortization of acquired inta
Slide 22: Supplemental Financial Information: Adjusted EBITDA Reconciliation
SUPPLEMENTAL FINANCIAL INFORMATION tec NON-GAAP RECONCILIATION - CONSOLIDATED ($000's) ADJUSTED EBITDA Q12% Q226 9324 Q424 202% Net loss, GAAP $ (49.495) $ (40,690) $ (39516) $ (33.332) $ (162123) $ (51.907) $ (41.144) $ (28578) $ (21.729) $ (143,358) $ (33,906) $ (25,781) Cash interest expense, net
Slide 23: Supplemental Financial Information: Non-GAAP P&L Trend
SUPPLEMENTAL FINANCIAL INFORMATION @C NON-GAAP P&L TREND - CONSOLIDATED ($000's) Q124 Q224 324 424 2024 Revenue from products and services $ 138,477 $ 145,573 $ 150719 $ 176,793 $ 611,562 $ 169,180 $ 185,544 $ 196,503 $ 212,928 $ 764,155 $ 192,108 $ 213,513 Non-GAAP cost of sales 40,336 41921 46243
Slide 24: Revenue Supplement
tec REVENUE SUPPLEMENT Q124 Q224 SUPPLEMENTAL FINANCIAL INFORMATION 9324 Revenues: Products and services - Surgical 122,617 130,028 135343 156,468 544,456 152,084 168,217 176,676 189,769 686,745 178,124 196,077 Products and services - EOS 15,860 15545 15376 20,325 67,106 17,096 17,327 19,827 23,159